MERTK, a member of the TAM (TYRO3, AXL and MERTK) family of RTKs, is overexpressed or ectopically expressed in approximately 70% of NSCLC and is an attractive biological target for the treatment of NSCLC (Linger et al., 2013; Graham et al., 2014). This evidence concerns the gene MERTK and non-small cell lung carcinoma.